head and neck cancer – Page 16

High Interest in HPV and EGRF When Referring to Head and Neck Cancer

Source: MedScape Today May 12, 2011 (London, United Kingdom) — The hottest topic in head and neck cancers is the role of human papillomavirus (HPV) in the disease, although there is also a lot interest in treatment with EGRF inhibitors, especially the second-generation products, according to an expert here at the European Society for Therapeutic Radiology and Oncology 11th Biennial Conference. HPV has only been associated with head and neck cancer in the last few years, but it is now clear that patients who are positive for the virus have a better prognosis, said Cai Grau, MD, DMSC, professor of oncology at Aarhus University Hospital, Denmark. He chaired a session during which both hot topics were discussed. "These patients have a better prognosis, irrespective of treatment, and their risk of a second cancer is virtually zero," added session participant Lisa Licitra, MD, medical oncologist at the Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan, Italy. However, there is a difference between patients in the United States and those in Europe with regard to risk, she told meeting attendees. For American patterns, Dr. Licitra cited the analysis published last year in the New England Journal of Medicine (2010;363:24-35), which reported a risk model for death from oropharyngeal squamous cell carcinoma on the basis of HPV status, pack-years of tobacco smoking, and tumor and nodal stage. In this 266-patient cohort, 43% were low risk, 30% were intermediate risk, and 27% were high risk. Dr. Licitra reported that when [...]

Oral Cancer Foundation News Team - A2011-05-12T10:12:51-07:00May, 2011|Oral Cancer News|

New Breath Test to Identify Head and Neck Cancer

Source: British Journal of Cancer M Hakim, S Billan, U Tisch, G Peng, I Dvrokind, O Marom, R Abdah-Bortnyak, A Kuten and H Haick Abstract Background: Head-and-neck cancer (HNC) is the eighth most common malignancy worldwide. It is often diagnosed late due to a lack of screening methods and overall cure is achieved in <50% of patients. Head-and-neck cancer sufferers often develop a second primary tumour that can affect the entire aero-digestive tract, mostly HNC or lung cancer (LC), making lifelong follow-up necessary. Methods: Alveolar breath was collected from 87 volunteers (HNC and LC patients and healthy controls) in a cross-sectional clinical trial. The discriminative power of a tailor-made Nanoscale Artificial Nose (NA-NOSE) based on an array of five gold nanoparticle sensors was tested, using 62 breath samples. The NA-NOSE signals were analysed to detect statistically significant differences between the sub-populations using (i) principal component analysis with ANOVA and Student's t-test and (ii) support vector machines and cross-validation. The identification of NA-NOSE patterns was supported by comparative analysis of the chemical composition of the breath through gas chromatography in conjunction with mass spectrometry (GC–MS), using 40 breath samples. Results: The NA-NOSE could clearly distinguish between (i) HNC patients and healthy controls, (ii) LC patients and healthy controls, and (iii) HNC and LC patients. The GC–MS analysis showed statistically significant differences in the chemical composition of the breath of the three groups. Conclusion: The presented results could lead to the development of a cost-effective, fast, and reliable method for the differential [...]

Oral Cancer Foundation News Team - A2011-05-11T10:55:38-07:00May, 2011|Oral Cancer News|

Spouses of Head/Neck Cancer Patients More Inclined to PTSD

Source: MedScape Today Partners of patients with newly diagnosed head and neck cancer are significantly more likely to meet research criteria for post-traumatic stress disorder (PTSD) than patients themselves, according to a study presented here at the Society of Behavioral Medicine 32nd Annual Meeting and Scientific Sessions. Donna Posluszny, PhD, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, and colleagues from there and from the University of Texas, Arlington, Texas, found that 8 of 20 partners of patients with head and neck cancer (20%) had a mean score on the PTSD Checklist (also known as the PCL) of 50 or higher, compared with only 2 of 40 patients (5%). Patients who score at least 50 on the PCL meet the criteria for PTSD. "This is not a formal diagnosis of PTSD but for research purposes, a score of 50 or higher is meaningful," Dr. Posluszny told delegates. "And we were very surprised to find that partners of patients with newly diagnosed head and neck cancer experience greater amounts of traumatic stress than patients themselves do." For the study, investigators recruited 40 dyads (2 individuals regarded as a pair) where the partner was considered to be a "romantic" partner. Some 78% of the patients were male, while most partners were female; all but a small minority were married. Almost all were white, and, as a cohort, they were somewhat better educated and made more money than the majority of patients with head and neck cancer. Sixty-five percent of them also had [...]

Oral Cancer Foundation News Team - A2011-05-09T09:49:39-07:00May, 2011|Oral Cancer News|

Lower survival rate for head and neck cancer patients who suffer from stress and depression

Source: Medical News Today Studies have shown that stress can affect the immune system and weaken the body's defense against infection and disease. In cancer patients this stress can also affect a tumor's ability to grow and spread. However, the biological mechanisms that underlie such associations are not well understood. Now, researchers at Fox Chase Cancer Center find that poor psychosocial functioning is associated with greater vascular endothelial growth factor (VEGF) expression - a signaling protein that not only stimulates tumor growth, but is also associated with shorter disease-free survival in head and neck cancer patients. "There is research showing that high VEGF expression in other cancers, such as ovarian, is associated with psychosocial factors," says Carolyn Fang, Ph.D., Co-Leader of the Cancer Prevention and Control Program at Fox Chase, who presented the study at the 32nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine on Thursday, April 28th. "This information coupled with what we already know about VEGF promoting tumor aggressiveness and poorer prognosis in head and neck cancer patients, certainly gave us a reason to look at this biomarker." VEGF not only plays a pivotal role in angiogenesis, but it is also regulated by stress hormones and key cytokines - a category of signaling molecules used extensively in intercellular communication. In the current study, Fang and colleagues looked at 37 newly diagnosed, pre-surgical head and neck cancer patients, to see if psychosocial functioning, such as perceived stress and depressive factors, was associated with VEGF, a [...]

Oral Cancer Foundation News Team - A2011-05-07T05:20:23-07:00May, 2011|Oral Cancer News|

Michael Douglas compliments Canadian health care

Source: The Globe and Mail Hollywood star Michael Douglas offered up high praise for Canadian health care on Tuesday in a nod to the Montreal medical staff who made the breakthrough diagnosis of his throat cancer. Mr. Douglas said a doctor at Montreal’s Jewish General Hospital detected the disease that had eluded specialists in the United States. In gratitude, the Oscar winner agreed to add a new role to his résumé: fundraising draw for Canadian medical research. The actor travelled to Montreal from New York on Tuesday to act as leading man for McGill University’s annual fundraiser for head and neck cancer research. In an interview at a Montreal ballroom where he was about to be honoree for the evening, a dapper-looking Mr. Douglas said getting the news was like being “hit by a truck.” Yet when it came, he said, he had suspected it for months. He said he’d been having bothersome symptoms over the course of nine months: pain in his throat, in the back of his gums and up toward his ears. He consulted various ear, nose and throat doctors and was prescribed antibiotics for what was thought to be an infection. But while summering last year in Quebec’s Mont Tremblant, where he shares a home with his wife, actress Catherine Zeta-Jones, Mr. Douglas went to see Dr. Saul Frenkiel at the Jewish General, a McGill teaching hospital. The doctor put a tongue depressor in the actor’s throat. “I looked in his eyes and I immediately knew [...]

Oral Cancer Foundation News Team - A2011-05-05T09:49:17-07:00May, 2011|Oral Cancer News|

HPV & oral sex: link to increase oral cancer in men

Fort Worth— Dana Wilson is one of an estimated 20- million Americans who have HPV which caused cancer in his tongue and neck. Dana remembers getting the news after going to the doctor to have a lump in his neck checked. "It was a moment that you would probably bleep me for saying on air," Dana said. "It was one of those oh, moments." Dr. Jerry Barker is an oncologist at Texas Oncology in Fort Worth and said there is much to be learned about HPV. A recent study suggested that open mouth kissing could be a way to transmit the virus--but Dr. Barker said one thing is certain. "There is clearly a distinct correlation between head and neck cancer and the number of oral sexual partners in a patient's lifetime," Dr. Barker said. "It's an epidemic of human papillomavirus worldwide." Dr. Barker said the virus is increasing at about 2% to 3% a year--approximately the same rate as head and neck cancers--and today fewer Americans smoke. "It's interesting that ten or twenty years ago the majority of men and women who have head and neck cancers had heavy smoking and drinking histories," Dr. Barker said. "Now it tends of be young, non-smokers that are getting these cancers. Dana was treated with a combination of radiation and chemotherapy--today he is cancer free and mentors other head and neck cancer patients. "Was I shocked? Yea," Dana said. "Because probably like a lot of people my initial reaction was HPV, that's a [...]

Oral Cancer Foundation News Team - A2011-05-07T05:18:38-07:00May, 2011|Oral Cancer News|

Protein inhibitor may supply contemporary HPV treatment

Source: Dr.Bicuspid.com Researchers from Tufts University School of Medicine have developed a protein-based inhibitor that could provide a topical treatment for HPV as an alternative to surgical and harsh chemical treatments (FASEB Journal, April 11, 2011). HPV affects about 20 million people in the U.S., making it the most common sexually transmitted infection. There are more than 100 types of HPV, of which more than 40 are sexually transmitted. These include two high-risk types, HPV-16 and HPV-18, which cause the majority of cervical and anogenital cancers, and some portion of head and neck cancers, particularly oral cavity and oropharynx cancers. "Currently, there is no cure for HPV, and the available treatment options involve destroying the affected tissue. We have developed a protein inhibitor that blocks HPV protein expression in cell culture, a first step toward a topically applied treatment for this cancer-causing virus," said senior author James Baleja, PhD, an associate professor of biochemistry at Tufts University School of Medicine. In their efforts to inhibit HPV, Baleja and his team zeroed in on the viral protein E2, which controls viral activities including DNA replication and the activation of cancer-causing genes. Using structure-guided design, the team developed a protein called E2R that prevents E2 from functioning normally. When the researchers applied E2R to a cell model of HPV biology, viral gene transcription was halted. Because HPV infects epithelial cells, the outermost layer of the skin, and the mucous membranes, protein inhibitors such as E2R could be applied in a topical form. [...]

Oral Cancer Foundation News Team - A2011-04-27T12:21:43-07:00April, 2011|Oral Cancer News|

Oral sex is a major risk factor for oral cancer in men

Source: AOL News Rates of oral cancer are on the rise among men, and researchers say the culprit isn't the devil you might think. The rising rates of oral cancer aren't being caused by tobacco, experts say, but by HPV, the same sexually transmitted virus responsible for the vast majority of cases of cervical cancer in women. Millions of women and girls have been vaccinated against HPV, or human papillomavirus, but doctors now say men exposed to the STD during oral sex are at risk as well and may have higher chances of developing oral cancer. John Moore, Getty Images About 65 percent of oral cancer tumors were linked to HPV in 2007, according to the National Cancer Institute. And the uptick isn't occurring among tobacco smokers. "We're looking at non-smokers who are predominantly white, upper middle class, college-educated men," Brian Hill, the executive director of the Oral Cancer Foundation, told AOL News by phone. Tobacco use has declined over the past decade, but rates of HPV infections have risen and affect at least 50 percent of the sexually active American population, according to the Centers for Disease Control. HPV-16, the strain of the virus that causes cervical cancer in women, has become the leading cause of oral cancer in non-smoking men, Hill said, citing research in the New England Journal of Medicine. "When the No. 1 cause of your disease goes down [tobacco use], you would expect that the incidence of disease would go down, but that hasn't happened," he said. [...]

Oral Cancer Foundation News Team - A2011-04-21T13:48:09-07:00April, 2011|OCF In The News, Oral Cancer News|

Oral tongue squamous cell carcinoma is on the rise in young caucasian females, age 18 to 44 years

Source: Journal of Clinical Oncology Abstract Purpose To evaluate the incidence of oral cavity squamous cell carcinoma (OCSCC) and oral tongue squamous cell carcinoma (OTSCC) in young white women, age 18 to 44 years. Patients and Methods We analyzed incidence and survival data from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute from 1975 to 2007 for OCSCC and OTSCC. Three cohorts were examined: all ages, age 18 to 44 years (ie, “young”), and age > 44 years. Individuals were stratified by sex and/or race. Percentage change (PC) and annual percentage change (APC) were calculated. Joinpoint regression analyses were performed to examine trend differences. Results Overall, incidence of OCSCC was decreasing for all ages. However, incidence was increasing for young white women (PC, 34.8; APC, 2.2; P < .05). Incidence of OTSCC was decreasing for all ages except in the age 18 to 44 years group (PC, 28.8; APC, 1.8; P < .05). Young white individuals had increasing incidence trends of OTSCC (white women: PC, 111.3; APC, 4; P < .05; young white men: PC, 43.7; APC, 1.6; P < .05). The APC of OTSCC was significantly greater in young white women compared with that in young white men (P = .007). Furthermore, incidence of SCC in all other subsites of the oral cavity was decreasing. Nonwhites had a decreasing incidence of OCSCC and OTSCC. Cause-specific survival was similar among whites age 18 to 44 and individuals older than age 44 years. Conclusion OTSCC [...]

Charlotte Parker2011-04-10T17:26:36-07:00April, 2011|Oral Cancer News|

HPV link comes as a shock to male cancer patients

By ANIKA CLARK Stanley Sikora of Fall River and Tom Souza of Swansea clearly remember when they started their battles with cancer — life-changing moments while raking leaves or shaving, when they touched their necks and felt a lump. It's a common experience thanks to a disease that, between the suffering of friends, families and ourselves, has become nearly universal. But then came news neither expected. Tumors from both men tested positive for human papillomavirus, an often sexually transmitted virus that is increasingly being linked to cancers of the head and neck. At Massachusetts General Hospital's Center for Head and Neck Cancers, "it's something that we see practically on a daily basis," said Dr. Lori Wirth, medical director for head and neck oncology, who said in an email that, although there are not-fully-understood co-factors, there's strong data that about 60-65 percent of all cancers of the oropharynx (the rear of the mouth, including the back of the throat, tonsils and the base of the tongue) are HPV-related. "Our awareness that HPV is associated with oropharynx cancers is something that has been emerging over the last 5-10 years," she said. "Ten years ago, we didn't even look for (it)." Upon learning of his HPV diagnosis, "I honestly felt creepy about myself," said Sikora, 59, albeit somewhat reassured when he found out how easily it's transmitted. "Already I was shocked that I got cancer. Now it's from HPV," he said. "So I'm thinking 'I can't be going around telling people I got [...]

Oral Cancer Foundation News Team - A2011-04-04T14:41:03-07:00April, 2011|Oral Cancer News|